<DOC>
	<DOCNO>NCT02694536</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter trial design evaluate safety erlotinib combination standard care chemotherapy ( gemcitabine ) participant locally advance , unresectable , metastatic pancreatic cancer .</brief_summary>
	<brief_title>A Study Erlotinib Locally Advanced , Unresectable , Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma locally advanced , unresectable , metastatic disease No prior systemic treatment metastatic disease Adjuvant therapy ≥6 month prior study entry residual toxic effect Eastern Cooperative Oncology Group ( ECOG ) performance status 0 3 Life expectancy ≥12 week Adequate hematologic , hepatic , renal function Negative pregnancy test within 72 hour study drug use effective contraception among woman childbearing potential Unstable systemic disease Prior systemic human epidermal growth factor receptor 1 ( HER1 ) epidermal growth factor receptor ( EGFR ) inhibitors Other malignancy within 5 year prior study entry Significant opthalmologic abnormality Inability take oral medication Need IV alimentation Prior surgery affect absorption Active peptic ulcer disease Nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>